ATLANTA, GA – – (Globe Newswire – April 17, 2025) – – A shareholder class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas BioPharma” or “the Company”) (NASDAQ: ZBIO). The lawsuit alleges that the Company’s Registration Statement contained materially false and/or misleading statements, and/or failed to disclose material adverse facts, including allegations that Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO.

If you bought shares of Zenas BioPharma pursuant and/or traceable to the Registration Statement and related prospectus issued in connection with its September 2024 IPO, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/zenas-biopharma/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is June 16, 2025.